

REMARKS

In the Office Action, claims 16-47 were subject to restriction and/or election requirement. In the present amendment, claims 16-31, 37-42, and 47 have been canceled without prejudice or disclaimer; claims 32-36 have been amended; and claims 48-51 have been added. Thus, claims 32-36, 43-46, and 48-51 are pending.

Applicants hereby elect Group I (drawn to a polynucleotide) and the nucleotide sequence of SEQ ID NO:13, which encodes the amino acid sequence of SEQ ID NO:14, without traverse.

The claims as amended herein are directed to the elected invention and are supported by the originally filed application. Claims 48-51 have been added to secure enhanced protection for Applicants' invention. Claim 48 is supported in the specification at page 3, lines 11-18. Claims 49 and 50 are supported in the specification at page 3, lines 15-18. Claim 51 is supported in the specification from page 13, line 36, through page 14, line 11. No new matter is believed to be added.

Please charge any requisite fees or credit any overpayment to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the application is earnestly solicited.

Respectfully submitted,



PAUL D. GOLIAN
ATTORNEY FOR APPLICANTS
REGISTRATION NO. 42,591
TELEPHONE: (302) 992-3749
FACSIMILE: (302) 892-1026

Dated: 4/9/02

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In showing the changes, deleted material is shown in brackets, and inserted material is shown underlined.

IN THE CLAIMS:

16-31. "canceled"

32. "amended" An isolated polynucleotide comprising:

(a) a nucleotide sequence encoding a polypeptide having extragenic suppressor activity, wherein the amino acid sequence of the polypeptide and the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:12,] SEQ ID NO:14[, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20] have at least 80% identity based on the Clustal alignment method, or

(b) the complement of the nucleotide sequence.

33. "amended" The polynucleotide of [C]claim 32, wherein the amino acid sequence of the polypeptide and the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:12,] SEQ ID NO:14[, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20] have at least 90% identity based on the Clustal alignment method.

34. "amended" The polynucleotide of [C]claim 32, wherein the amino acid sequence of the polypeptide and the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:12,] SEQ ID NO:14[, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20] have at least 95% identity based on the Clustal alignment method.

35. "amended" The polynucleotide of claim 32 comprising the nucleotide sequence of [SEQ ID NO:9, SEQ ID NO:11,] SEQ ID NO:13[, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:19].

36. "amended" The polynucleotide of claim 32, wherein the polypeptide comprises the amino acid sequence of [SEQ ID NO:10, SEQ ID NO:12,] SEQ ID NO:14[, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20].

37-42. "canceled"

47. "canceled"

48-51. "added"